A Phase 2 interventional study of Azacitidine and Laboratory Biomarker Analysis in Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 and Chronic Myelomonocytic Leukemia-2, sponsored by National Cancer Institute (NCI). Active, not recruiting at 294 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic — 3 open to participants now, 8 under way, 1 of them phase 3. Azacitidine · Leukemia, Myelomonocytic, Chronic.
Among the 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2012, is one of 16 in phase 2, and was the 17th registered.
540 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 68 are open to participants now.
Browse Leukemia, Myelomonocytic, Chronic studies →3 of the 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic are open now, in 1 country. Recruiting first, the newest first:
Douglas Tremblay · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 62 Leukemia, Myelomonocytic, Chronic studies recruiting now, 47 (76%) set no upper age limit and 7 (11%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 26 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 40 across 430 interventional studies indexed under Leukemia, Myelomonocytic, Chronic.
Median enrollment 34 across the 37 interventional studies. Of the 28 that completed or were terminated, 12 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 38 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
41 studies in Leukemia, Myelomonocytic, Chronic by National Cancer Institute (NCI): 1 open now, 7 under way, 1 of them phase 3. Of 34 finished, 9 (26%) have results posted.
Among the 41 studies in Leukemia, Myelomonocytic, Chronic by National Cancer Institute (NCI), this one is the 2nd largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2012, is one of 15 in phase 2, and was the 34th registered.
National Cancer Institute (NCI)’s Leukemia, Myelomonocytic, Chronic studies by the year they started, since 1996.
4 of the studies testing azacitidine in Leukemia, Myelomonocytic, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
| NCT06159491Douglas TremblayPacritinib in CMML | 2027-07 |
| NCT03683433M.D. Anderson Cancer CenterEnasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | 2027-09-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among National Cancer Institute (NCI)’s 41 in Leukemia, Myelomonocytic, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
PRIMARY OBJECTIVES:
I. To select based on response rate (complete remission, partial remission, or hematologic improvement) either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine for further testing against single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase II) II. To compare overall survival between the combination arm selected in the Phase II portion of the trial to single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase III)
SECONDARY OBJECTIVES:
I. To estimate relapse-free survival, overall survival and cytogenetic response rate of patients treated on each regimen.
II. To estimate the frequency and severity of toxicities of the three regimens in this patient population.
III. To investigate in a preliminary manner the frequency of subgroups from prestudy cytogenetic studies and correlate these subgroups with clinical outcomes in this patient population.
IV. To collect specimens for banking for use in future research studies.
TERTIARY OBJECTIVES:
I. To evaluate the prevalence of a pre-specified list of molecular lesions (48 total lesions).
II. To assess associations of these lesions with outcomes (response, event-free survival, relapse-free survival, and overall survival).
III. To develop a deoxyribonucleic acid (DNA) methylation biomarker predictive of response to DMTi treatment in MDS.
IV. To harness gene expression profiles as clinical biomarkers of primary resistance to DMTi in MDS.
OUTLINE: Patients are randomized to 1 of 3 treatment arms. In Phase III, patients are randomized to 1 of 2 treatment arms (the combination arm selected in Phase II or the single-agent azacitidine arm).
ARM I: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 or days 1-5 and 8-9, and lenalidomide orally (PO) once daily (QD) on days 1-21.
ARM II: Patients receive azacitidine as in Arm I.
ARM III: Patients receive azacitidine as in Arm I and vorinostat PO twice daily (BID) on days 3-9.
In all arms, treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Inclusion Criteria:
Patients must have morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) based on one of the following:
French-American-British (FAB) classifications:
World Health Organization (WHO) classifications:
Females of (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to registration; FCBP must agree to have a second pregnancy test within 24 hours prior to starting cycle 1 if randomized to receive lenalidomide
Cytogenetics requirements:
Banking requirements:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
Drug: Azacitidine · Other: Laboratory Biomarker Analysis · Drug: Lenalidomide
Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
Drug: Azacitidine · Other: Laboratory Biomarker Analysis
Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
Drug: Azacitidine · Other: Laboratory Biomarker Analysis · Drug: Vorinostat
Given SC or IV
Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza
Correlative studies
Given PO
Also known as: CC 5013, CC-5013, CC5013, CDC 501, Revlimid
Given PO
Also known as: L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
Response Rate (Phase II)
A response is any of complete hematological remission, partial remission, or hematologic improvement.
Time frame: Up to 5 years
Overall Survival (Phase III)
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm.
Time frame: Up to 5 years
Relapse-free Survival
RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method.
Time frame: Up to 5 years
Overall Survival
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.
Time frame: Up to 5 years
Pre-study Cytogenetic Abnormalities
Cytogenetic risk group is used to identify cytogenetic abnormalities.
Time frame: Up to 5 years
Toxicity Rate
Adverse events that are possibly, probably or definitely related to study drug are reported.
Time frame: Up to 5 years
| Milestone | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Started | 97 | 92 | 93 |
| Completed | 0 | 0 | 0 |
| Not completed | 97 | 92 | 93 |
| Withdrew: Ineligible | 4 | 0 | 1 |
| Withdrew: Death | 7 | 6 | 2 |
| Withdrew: Still on treatment | 9 | 9 | 6 |
| Withdrew: Disease progression | 28 | 30 | 25 |
| Withdrew: Adverse event | 17 | 7 | 18 |
| Withdrew: Refusal unrelated to adverse event | 10 | 13 | 14 |
| Withdrew: Not protocol specified | 22 | 27 | 27 |
A response is any of complete hematological remission, partial remission, or hematologic improvement.
| percentage of patients having a response | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Response Rate (Phase II) | 49 (39 to 60) | 38 (28 to 49) | 27 (18 to 37) |
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm.
No measurements were reported for this outcome.
RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method.
| Days | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Relapse-free Survival | 435 (237 to 546) | 311 (182 to 640) | 455 (197 to NA) |
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.
| Days | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Overall Survival | 588 (426 to 737) | 449 (356 to 603) | 527 (392 to 852) |
Cytogenetic risk group is used to identify cytogenetic abnormalities.
| participants | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Good/very good | 35 | 29 | 34 |
| Intermediate | 13 | 16 | 18 |
| Poor | 8 | 10 | 8 |
| Very poor | 23 | 23 | 19 |
| Missing | 14 | 14 | 13 |
Adverse events that are possibly, probably or definitely related to study drug are reported.
| Participants | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Abdominal infection | 1 | 0 | 0 |
| Abdominal pain | 1 | 0 | 3 |
| Acute kidney injury | 0 | 0 | 1 |
| Adult respiratory distress syndrome | 1 | 0 | 0 |
| Alanine aminotransferase increased | 0 | 0 | 5 |
| Anemia | 48 | 37 | 44 |
| Anorectal infection | 0 | 0 | 1 |
| Anorexia | 4 | 0 | 3 |
| Apnea | 0 | 0 | 1 |
| Ascites | 1 | 0 | 1 |
| Aspartate aminotransferase increased | 0 | 0 | 3 |
| Ataxia | 0 | 0 | 1 |
| Back pain | 1 | 0 | 0 |
| Blood and lymphatic system disorders - Other | 0 | 2 | 1 |
| Blood bilirubin increased | 0 | 0 | 3 |
| Bronchial infection | 0 | 0 | 1 |
| CD4 lymphocytes decreased | 1 | 0 | 0 |
| Cardiac arrest | 1 | 0 | 0 |
| Catheter related infection | 1 | 2 | 1 |
| Cecal infection | 0 | 0 | 1 |
| Cholecystitis | 0 | 0 | 1 |
| Colitis | 0 | 0 | 1 |
| Confusion | 0 | 0 | 1 |
| Constipation | 2 | 1 | 1 |
| Creatinine increased | 2 | 0 | 0 |
| Dehydration | 5 | 1 | 3 |
| Delirium | 0 | 0 | 1 |
| Diarrhea | 5 | 0 | 3 |
| Dizziness | 1 | 0 | 0 |
| Dyspnea | 4 | 2 | 3 |
| Epistaxis | 0 | 0 | 1 |
| Esophageal pain | 0 | 0 | 1 |
| Esophagitis | 1 | 0 | 0 |
| Fall | 0 | 0 | 1 |
| Fatigue | 9 | 6 | 14 |
| Febrile neutropenia | 16 | 11 | 13 |
| Fever | 0 | 0 | 2 |
| Flushing | 0 | 0 | 1 |
| Gastric hemorrhage | 0 | 0 | 1 |
| Gastrointestinal pain | 1 | 0 | 1 |
| General disorders and admin site conditions-Other | 1 | 0 | 0 |
| Generalized muscle weakness | 3 | 1 | 3 |
| Hallucinations | 0 | 0 | 1 |
| Headache | 0 | 0 | 1 |
| Heart failure | 0 | 0 | 1 |
| Hematoma | 0 | 0 | 1 |
| Hematuria | 1 | 0 | 2 |
| Hyperglycemia | 1 | 1 | 2 |
| Hypernatremia | 0 | 1 | 0 |
| Hypertension | 1 | 0 | 2 |
| Hyperuricemia | 0 | 0 | 1 |
| Hypoalbuminemia | 3 | 0 | 0 |
| Hypokalemia | 4 | 0 | 1 |
| Hypomagnesemia | 1 | 0 | 0 |
| Hyponatremia | 5 | 1 | 4 |
| Hypophosphatemia | 1 | 0 | 2 |
| Hypotension | 4 | 0 | 3 |
| Hypoxia | 0 | 0 | 1 |
| Infections and infestations - Other, specify | 4 | 2 | 5 |
| Intracranial hemorrhage | 1 | 0 | 0 |
| Investigations - Other, specify | 1 | 0 | 0 |
| Leukocytosis | 0 | 1 | 0 |
| Lower gastrointestinal hemorrhage | 0 | 0 | 2 |
| Lung infection | 4 | 1 | 2 |
| Lymphocyte count decreased | 14 | 9 | 3 |
| Lymphocyte count increased | 0 | 1 | 1 |
| Mucosal infection | 0 | 0 | 1 |
| Mucositis oral | 1 | 0 | 0 |
| Nausea | 1 | 2 | 2 |
| Neutrophil count decreased | 69 | 48 | 63 |
| Pain | 1 | 0 | 0 |
| Papulopustular rash | 1 | 0 | 0 |
| Pericardial effusion | 1 | 0 | 0 |
| Platelet count decreased | 61 | 46 | 64 |
| Pneumonitis | 0 | 0 | 1 |
| Pruritus | 1 | 0 | 0 |
| Pulmonary edema | 0 | 0 | 1 |
| Purpura | 1 | 0 | 0 |
| Rash maculo-papular | 13 | 3 | 1 |
| Renal and urinary disorders - Other, specify | 0 | 0 | 1 |
| Respiratory failure | 0 | 0 | 1 |
| Sepsis | 4 | 2 | 3 |
| Sinus bradycardia | 1 | 0 | 0 |
| Skin infection | 3 | 1 | 2 |
| Soft tissue infection | 1 | 1 | 0 |
| Sudden death NOS | 0 | 1 | 0 |
| Syncope | 2 | 0 | 4 |
| Thromboembolic event | 1 | 0 | 1 |
| Tooth infection | 0 | 0 | 1 |
| Upper gastrointestinal hemorrhage | 0 | 0 | 1 |
| Upper respiratory infection | 0 | 1 | 0 |
| Urinary tract infection | 1 | 1 | 1 |
| Vascular disorders - Other, specify | 0 | 0 | 1 |
| Vomiting | 1 | 1 | 1 |
| Weight loss | 1 | 0 | 0 |
| White blood cell decreased | 48 | 34 | 44 |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Azacitidine/Lenalidomide | — | 37/89 (41.6%) | 88/89 (98.9%) |
| Arm 2: Azacitidine | — | 8/91 (8.8%) | 89/91 (97.8%) |
| Arm 3: Azacitidine/Vorinostat | — | 47/91 (51.6%) | 91/91 (100%) |
| Event | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Infections and infestations-OtherInfections and infestations | 4/89 | 0/91 | 8/91 |
| Platelet count decreasedInvestigations | 7/89 | 0/91 | 8/91 |
| AnemiaBlood and lymphatic system disorders | 6/89 | 0/91 | 6/91 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/89 | 1/91 | 2/91 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/89 | 0/91 | 2/91 |
| FeverGeneral disorders | 1/89 | 0/91 | 6/91 |
| Lung infectionInfections and infestations | 5/89 | 0/91 | 4/91 |
| Abdominal painGastrointestinal disorders | 0/89 | 0/91 | 5/91 |
| Atrial fibrillationCardiac disorders | 4/89 | 0/91 | 0/91 |
| SepsisInfections and infestations | 4/89 | 2/91 | 4/91 |
| Event | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat |
|---|---|---|---|
| Platelet count decreasedInvestigations | 78/89 | 68/91 | 69/91 |
| Neutrophil count decreasedInvestigations | 77/89 | 58/91 | 73/91 |
| AnemiaBlood and lymphatic system disorders | 76/89 | 71/91 | 72/91 |
| FatigueGeneral disorders | 74/89 | 69/91 | 74/91 |
| White blood cell decreasedInvestigations | 66/89 | 52/91 | 60/91 |
| NauseaGastrointestinal disorders | 38/89 | 42/91 | 61/91 |
| ConstipationGastrointestinal disorders | 49/89 | 54/91 | 44/91 |
| DiarrheaGastrointestinal disorders | 42/89 | 23/91 | 53/91 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 46/89 | 20/91 | 16/91 |
| AnorexiaMetabolism and nutrition disorders | 39/89 | 31/91 | 45/91 |
Analysis includes eligible patients only.
| Age, Continuous(years) | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat | Total |
|---|---|---|---|---|
| Median | 70.81 (51.29 to 86.68) | 69.67 (42.69 to 88.96) | 70.36 (28.69 to 93.01) | 70.18 (28.69 to 93.01) |
| Sex: Female, Male(Participants) | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat | Total |
|---|---|---|---|---|
| Female | 32 | 31 | 22 | 85 |
| Male | 61 | 61 | 70 | 192 |
| Race (NIH/OMB)(Participants) | Arm 1: Azacitidine/Lenalidomide | Arm 2: Azacitidine | Arm 3: Azacitidine/Vorinostat | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 1 | 4 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 4 | 9 |
| White | 86 | 80 | 83 | 249 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 5 | 1 | 9 |
Showing the first 100 of 294 sites across 2 countries. Choose a country and city above to see the rest.
Ran from Mar 2012 to primary completion in Jun 2015, 39 months.
Results were first posted in Mar 2016, 9 months after primary completion.
Of 62 non-industry phase 2 interventional studies under Leukemia, Myelomonocytic, Chronic, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 111. This study's 39 months is below that.
Counting every sponsor, half of 69 studies reached it within 68 months; a quarter within 46 and three quarters within 110.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine
Leukemia, Myelomonocytic, Chronic →
National Cancer Institute (NCI) →